Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).
暂无分享，去创建一个
L. Bubendorf | R. Stahel | S. Peters | T. Stinchcombe | M. Tiseo | C. Baik | Michael W. Lu | P. Bonomi | D. Isla | S. Stanzel | J. Castro | D. Kowalski | A. Villegas | P. López | A. Rittmeyer | L. Lam | L. H. Lam | S. de Haas | S. Haas | T. Stinchcombe | R. A. Stahel | Augusto E. Villegas | C. Baik | Javier de Castro | P. Garrido Lopez | Sven Franz Stanzel